Celyad Oncology רווח לפני ריבית ומס (EBIT) 2024

מה עושה Celyad Oncology?

Celyad Oncology is a biotech company specializing in the discovery and development of new cancer immunotherapies. The company, headquartered in Mont-Saint-Guibert, Belgium, was founded in 2007 and has been listed on the NASDAQ and Euronext stock exchanges since September 2015. The history of Celyad Oncology began with the discovery of CAR-T therapy, which is based on the tumor cell recognition by T cells of the body's immune system. In 2001, researchers at the University of Leuven (Belgium) introduced a new method for culturing T cells, which was a major step in the development of CAR-T therapy. In 2004, the researchers founded Celyad with the aim of developing clinically effective CAR-T therapies. In 2015, the company was renamed Celyad Oncology to emphasize its strategic focus on oncology products. Celyad Oncology has developed a unique business model that focuses on the clinical development of CAR-T cell therapies. The company uses innovative technologies such as allogeneic CAR-T cells, which come from donor tissue from persons other than the patient. These cells have the advantage of being able to be produced in unlimited quantities, enabling the rapid and cost-effective manufacturing of CAR-T cells. In addition, the company has developed a platform technology called "shRNA" that regulates gene expression in T cells, thereby improving the safety and efficacy of CAR-T therapies. The company is divided into various divisions, from preclinical research to the clinical development and commercialization of CAR-T therapies. Celyad Oncology has several product candidates in various stages of development, focusing on indications such as multiple myeloma, acute myeloid leukemia (AML), and solid tumors. One of Celyad Oncology's most promising product candidates is CYAD-01, a CAR-T cell product targeting the CD19 protein. It is currently in a Phase I/IIa clinical trial evaluating the safety and efficacy of CYAD-01 in patients with refractory or relapsed CD19+ B-cell lymphoma. In October 2020, the product candidate achieved a complete response in a patient with a different indication, acute myeloid leukemia (AML). Another product candidate is CYAD-101, an allogeneic CAR-T cell product targeting the NKG2D protein. This protein is overexpressed on many cancer cells but not on healthy cells. CYAD-101 is currently in a Phase I/II clinical trial for the treatment of various tumor types, including lung cancer and pancreatic cancer. Celyad Oncology also collaborates with other companies to further develop its technologies and product candidates. In 2018, the company entered into a partnership with Novartis to utilize Celyad Oncology's CAR-T platform technology for the development of products for solid tumors. In 2019, Celyad Oncology announced a partnership with ONO Pharmaceutical to accelerate the development of CYAD-211, an allogeneic CAR-T cell product for the treatment of multiple myeloma. In summary, Celyad Oncology has not only a unique business model but also promising product candidates and technologies that have the potential to revolutionize the treatment of cancer. With a strong pipeline and targeted clinical development, Celyad Oncology is well positioned to continue its success in the future. Celyad Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.